Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis
This randomized controlled, multi-center study will carry out to assess the efficacy of GB-0998 compared to plasmapheresis in the treatment of the generalized Myasthenia Gravis based on the changes in Quantitative Myasthenia Gravis score (QMG score) as primary endpoint, and in addition, to assess the safety of GB-0998
Generalized Myasthenia Gravis
BIOLOGICAL: GB-0998 (Intravenous immunoglobulin)|PROCEDURE: Plasmapheresis
Changes in QMG score, at 4 weeks
Changes of QMG score, MG-ADL scale, anti-acetylcholine receptor antibody levels, from beginning of the treatment through 4th week
This randomized controlled, multi-center study will carry out to assess the efficacy of GB-0998 compared to plasmapheresis in the treatment of the generalized Myasthenia Gravis based on the changes in Quantitative Myasthenia Gravis score (QMG score) as primary endpoint, and in addition, to assess the safety of GB-0998